X4 Pharmaceuticals, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, X4 Pharmaceuticals is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $3.20, 31.5% below its 52-week high and below its 200-day average, which is falling.

$3.20

+6.31% today

$317M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is XFOR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 25w

S4 26w

S1 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 6w → S4 18w → S1 11w → S2 7w → S3 5w → S4 25w → S1 9w → S4 26w → S1 16w → S2 7w → S3 6w → S2 10w → S3 10w → S2 4w → S3 1w → S4 4w current

Total tracked: 166 weeks across 16 stage runs.

XFOR among Biotechnology184th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…184	XFORX4 Pharmaceuticals, Inc.	Stage 4 · wk 5	56	+2.9%

vs 52W High

-31.5%

$2.45 lo$4.67 hi

31.5% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-16.2%

200 DMA: $3.82 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.67x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+2.9%

-16.9%

-25.2%

YTD

-17.7%

+1.9%

Scan Membership

Breakout Watch

Latest: 2024-04-17

6 appearances in last 60 days. First seen: 2019-04-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.67x

2026-10-21S4

Wk 5 · Vol 0.38x

2026-10-20S4

Wk 4 · Vol 0.66x

2026-10-19S4

Wk 4 · Vol 0.66x

2026-10-16S4

Wk 4 · Vol 1.06x

2026-10-15S4

Wk 4 · Vol 0.61x

2026-10-14S4

Wk 4 · Vol 0.78x

2026-10-13S4

Wk 3 · Vol 0.49x

2026-10-12S4

Wk 3 · Vol 0.45x

2026-10-09S4

Wk 3 · Vol 0.60x

2026-10-08S4

Wk 3 · Vol 0.93x

2026-10-07S4

Wk 3 · Vol 0.48x

Moving averages & range

50 DMA

$3.43

200 DMA

$3.82

52W High

$4.67

52W Low

$2.45

5D Low

$2.59

Resistance levels (recent highs)

20d High

$3.20

60d High

$4.64

120d High

$4.67

250d High

$4.67

Next resistance

+45.0%

to 60d High

P/E (TTM)

160.0

Forward -4.2

ROE

-113.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.0

X4 Pharmaceuticals: quick answers

What stage is X4 Pharmaceuticals in?

As of Oct 22, 2026, X4 Pharmaceuticals (XFOR) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean

Is X4 Pharmaceuticals in an uptrend?

No. X4 Pharmaceuticals is in a Stage 4 downtrend. It trades 16.2% below its 200-day average, which is falling.

How far is X4 Pharmaceuticals from its 52-week high?

X4 Pharmaceuticals closed at $3.20 on Oct 22, 2026, 31.5% below its 52-week high of $4.67. Its 52-week low is $2.45.

How has X4 Pharmaceuticals performed over the past year?

As of Oct 22, 2026, X4 Pharmaceuticals is up 1.9% over the past year and down 17.7% so far in 2026.

Which sector and industry is X4 Pharmaceuticals in?

X4 Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.